{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39(18)"],"submitter":["Hutchings M"],"pubmed_abstract":["<h4>Purpose</h4>Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (<i>Gpt</i>) to reduce toxicity, are presented.<h4>Methods</h4>Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg <i>Gpt</i>. Dose-escalation steps were determined using a Bayesian continuous reassessment method with overdose control. Primary end points were safety, pharmacokinetics, and the maximum tolerated dose of glofitamab.<h4>Results</h4>Following initial single-patient cohorts, 171 patients were treate"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["1959-1970"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8210975"],"repository":["biostudies-literature"],"pubmed_title":["Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial."],"pmcid":["PMC8210975"],"pubmed_authors":["Morschhauser F","Iacoboni G","Carlile DJ","Hutchings M","Lundberg L","Thomas DN","Salles G","Dimier N","Carlo-Stella C","Dickinson MJ","Moore T","Umana P","Bacac M","Sureda A","Ferlini C","Morcos PN","Perez-Callejo D","Offner FC","Crump M","Broske AE","Belousov A","Weisser M","Martinez-Lopez J"],"additional_accession":[]},"is_claimable":false,"name":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.","description":"<h4>Purpose</h4>Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (<i>Gpt</i>) to reduce toxicity, are presented.<h4>Methods</h4>Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg <i>Gpt</i>. Dose-escalation steps were determined using a Bayesian continuous reassessment method with overdose control. Primary end points were safety, pharmacokinetics, and the maximum tolerated dose of glofitamab.<h4>Results</h4>Following initial single-patient cohorts, 171 patients were treate","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-06-01T00:45:35.381Z","creation":"2024-11-13T08:30:04.395Z"},"accession":"S-EPMC8210975","cross_references":{"pubmed":["33739857"],"doi":["10.1200/JCO.20.03175"]}}